SCTA01 not checked

Sinocelltech

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
4 in total

What this is

How it works
How it works isn't classified yet
Tested for
COVID-19, SARS-CoV-2
Main trialPhase 2/3
“The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III clinical trial. It will be conducted at selected investigational sites globally. The study is comprised of 2 parts.”In the company’s words, NCT04709328 on ClinicalTrials.gov

Other drugs for COVID-19

All 43 drugs for COVID-19

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2/3Not yet recruiting 1 Jan 2022 To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19
Phase 2/3Unknown 25 May 2021 The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care
Phase 2/3Terminated 29 Dec 2021 The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19
Phase 1Completed 17 Nov 2020 Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow SCTA01

Following is part of Solo: you see every change to SCTA01 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in